BioSpace News Archive

Sinaptica Therapeutics, Inc. today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot.

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has granted Cosentyx® (secukinumab) with a Notice of Compliance (NOC) for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy – representing a safe and efficacious new treatment option for Canadians living with the condition.

Upstream Bio, Inc.today presented clinical data from its dose-ranging study of verekitug (UPB-101) in adults with asthma, at the American Thoracic Society International Conference being held in San Diego, CA.

Cambridge Biotherapies proudly announces the launch of Ketamine Infusions for Pain and Headache Management, now available at all locations.

Virios Therapeutics, Inc. today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share.

Inventiva announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver on June 5-8, 2024 in Milan, Italy.

Aligos Therapeutics, Inc. today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Soleno Therapeutics, Inc. today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering.

CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 22, 2024, payable on July 5, 2024, to all shareholders of record as of June 14, 2024.